Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Commentary|Podcasts|June 4, 2026
Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape
Author(s)Michael Christel, Jesse Mendelsohn
Model N Senior Vice President Jesse Mendelsohn explores the hidden costs and realities of PBM-driven drug pricing and the growing challenges manufacturers face in ensuring contract compliance, formulary access and reimbursement accuracy.
Advertisement
In this Pharmaceutical Executive podcast episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to offer a candid, expert-driven look at the pharmacy benefit manager (PBM) landscape, including the operational complexities confronting biopharma organizations and what these companies must understand to protect their revenue and expand patient access. Mendelsohn cuts through the spin to examine where PBM reform efforts are progressing and falling short, how payer vertical integration is compounding financial risk for manufacturers and why the onus increasingly falls on drugmakers themselves to police the data, the contracts and the dollars at stake.
01:32 - PBM scrutiny: Where it’s missing the mark
05:54 - Pharma’s chief PBM concerns
08:08 - Formulary compliance and transparency
12:00 - Data correlation and rebate accuracy
18:00 - Addressing multipayer-claim complexity
19:03 - Benefit-claim breakdowns: The 340B effect
20:14 - Why coordination issues persist
21:16 - Independent PBMs: Is their model game-changing?
26:01 - PBM reform potential and pace
29:09 - Future pressure points for manufacturers
Click below to listen to the audio version and subscribe to the Pharmaceutical Executive Podcast:
Advertisement
Related to this article
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.
Joe Cunningham argues that the most-favored-nation drug pricing agreements carry no legislative weight and discusses what the program actually locks in.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Bristol Myers Squibb’s Wendy Short Bartie on recasting corporate affairs as an enterprise value engine that connects trust, access and the patient voice.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
3
Pharmaceutical Executive Daily: FDA Approves Fayuvi
4
Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham
5